Cynthia Collins's Insider Trades & SAST Disclosures
Cynthia Collins's most recent trade in Codexis Inc. was a trade of 71,174 Common Stock done . Disclosure was reported to the exchange on March 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Cynthia Collins.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Codexis Inc. | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 71,174 | 71,174 (0%) | 0% | 0 | Common Stock | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 87,440 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | 08 Jan 2025 | 58,950 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 28,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2024 | 97,698 | 97,698 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2024 | 51,679 | 51,679 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 19,650 | 58,950 | - | 0 | Common Stock | |
| Certara Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 11,928 | 11,928 | - | - | Restricted Stock Units | |
| Certara Inc | Cynthia Collins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Cynthia Collins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 24,161 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 19,650 | 39,300 | - | 0 | Common Stock | |
| DermTech Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 35,714 | 104,835 (0%) | 0% | 0 | Common Stock | |
| Certara Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 8,663 | 8,663 | - | - | Restricted Stock Units | |
| Certara Inc | Cynthia Collins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 9,067 | 15,498 | - | 0 | Common Stock | |
| Certara Inc | Cynthia Collins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 9,067 | 0 | - | - | Restricted Stock Units | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 28,500 | 28,500 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 19,650 | 19,650 | - | 0 | Common Stock | |
| DermTech Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 26,480 | 69,121 (0%) | 0% | 0 | Common Stock | |
| Certara Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 9,067 | 9,067 | - | - | Restricted Stock Units | |
| Poseida Therapeutics Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2021 | 87,440 | 87,440 | - | - | Stock Option (Right to Buy) | |
| Editas Medicine Inc | Cynthia Collins | CEO | Sale of securities on an exchange or to another person at price $ 66.65 per share. | 09 Feb 2021 | 1,262 | 43,760 (0%) | 0% | 66.6 | 84,112 | Common Stock |
| Editas Medicine Inc | Cynthia Collins | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.66 per share. | 20 Aug 2020 | 1,976 | 45,022 (0%) | 0% | 36.7 | 72,440 | Common Stock |
| DermTech Inc | Cynthia Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 8,000 | 33,483 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges